PharmaShots Interview

PharmaShots Interview: Dr. Phillip Mease Shares Insights on the Clinical data of Tremfya (guselkumab) Presented in the Lancet

In an interview with PharmaShots, Dr. Phillip Mease, MD, Seattle Rheumatology Associates shares insights on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in The Lancet Shots: The P-III trials consist of two studies i.e., DISCOVER-1 & 2 evaluates Tremfya in 1100 patients with PsA who have axial symptoms The results demonstrated efficacy in …

PharmaShots Interview: Dr. Phillip Mease Shares Insights on the Clinical data of Tremfya (guselkumab) Presented in the Lancet Read More »

PharmaShots Interview: Durect’s James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021

In an interview with PharmaShots, James E. Brown, President, CEO, and Director of Durect shared his views on the clinical data of DUR-928 in P-1b trial for NASH and P-I trial for Hepatic Impairment Shots: The P-Ib trial evaluates DUR-928 (50/150/600mg for 4wks.) in 65 patients with NASH with stage 1-3 fibrosis which showed improvement …

PharmaShots Interview: Durect’s James E. Brown Shares Insight on the Data of DUR-928 Presented at EASL 2021 Read More »

PharmaShots Interview: TFF’s Dr. Dale Christensen Shares Insight on the Thin Film Freezing Technology

In an interview with PharmaShots, Dr. Dale Christensen, Ph.D., Director of Clinical Development at TFF Pharmaceuticals shared his views on the preliminary data from the P-I trial of inhalable tacrolimus powder formulation for Lung Transplant & its TFF technology Shots: TFF has developed an inhalable tacrolimus powder formulation that can be delivered directly to the …

PharmaShots Interview: TFF’s Dr. Dale Christensen Shares Insight on the Thin Film Freezing Technology Read More »

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds

In an interview with PharmaShots, James Graham, CEO of Recce Pharmaceuticals shared his views on the multiple patient dosing in P-I/II clinical trial of RECCE 327 (R327) for the treatment of infected burn wounds. Shots: The multiple patients have been dosed in P-I/II trial evaluates the effectiveness & safety of RECCE 327 in 30 patients …

PharmaShots Interview: Recce Pharmaceuticals’ James Graham Shares Insight on the P-I/II Clinical Trial of RECCE 327 (R327) for Infected Burn Wounds Read More »

PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021

In an interview with PharmaShots, Dr. Ian Walters, CEO of Portage Biotech shared his views on the interim data from the P-II IT-01 trial evaluates the safety and efficacy of INT230-6 as both a monotherapy and in combination with pembrolizumab or ipilimumab in solid tumors Shots: The P-II IT-01 trial evaluates the safety & efficacy …

PharmaShots Interview: Portage Biotech’s Dr. Ian Walters Shares Insight on the Data of INT230-6 Presented at ASCO 2021 Read More »

Exclusive Interview with PharmaShots: Kelly Pokuta and April Kunze of Prime Therapeutics Share Insight on MedDrive, a Medical Drug Management Program

In an exclusive interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with its Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical …

Exclusive Interview with PharmaShots: Kelly Pokuta and April Kunze of Prime Therapeutics Share Insight on MedDrive, a Medical Drug Management Program Read More »

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System

In an interview with PharmaShots, Michael Dale, Senior Vice President of the Structural Heart division at Abbott shared his views on the Navitor’s approval in the EU for patients with severe aortic stenosis who are at high or extreme surgical risk for open-heart surgery. Shots: Abbott has received CE Mark approval for its latest-generation transcatheter …

PharmaShots Interview: Abbott’s Michael Dale Shares Insight on the CE Mark for the Next-Generation Navitor TAVI System Read More »

PharmaShots Interview: Saniona’s Rami Levin Shares Insight on Tesomet for Hypothalamic Obesity

In an interview with PharmaShots, Rami Levin, Chief Executive Officer at Saniona shared his views on the US FDA’s ODD to Tesomet for the treatment of hypothalamic obesity (HO) and discuss its role in the company’s continued pipeline progress. Shots: Saniona reported that the FDA has granted orphan drug designation to Tesomet for the treatment …

PharmaShots Interview: Saniona’s Rami Levin Shares Insight on Tesomet for Hypothalamic Obesity Read More »

PharmaShots Interview: Rain Therapeutic’s Avanish Vellanki Shares Insight on the Initiation of P-III MANTRA Trial of Milademetan for Dedifferentiated Liposarcoma

In an interview with PharmaShots, Avanish Vellanki, CEO and Cofounder at Rain Therapeutics shared his views on the initiation of the P-III MANTRA trial to evaluate the safety & efficacy of Milademetan for dedifferentiated liposarcoma and provide updates about the company’s lead candidate, RAIN-32. Shots: The company initiates P-III MANTRA trial to evaluate safety & …

PharmaShots Interview: Rain Therapeutic’s Avanish Vellanki Shares Insight on the Initiation of P-III MANTRA Trial of Milademetan for Dedifferentiated Liposarcoma Read More »

PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis

In an interview with PharmaShots, Jonathan Rigby, Group Chief Executive Officer at Revolo Biotherapeutics shared his views on the unique mechanism of ‘1104 and discuss the plan of the company’s clinical studies. Shots: Revolo reported the US FDA’s approval to initiate a P-II clinical trial evaluating the safety and efficacy of ‘1104 in adults with …

PharmaShots Interview: Revolo’s Jonathan Rigby Shares Insights on the ‘1104 for Eosinophilic Esophagitis Read More »

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease

In an interview with PharmaShots, Andrew Greenspan, VP, Immunology Affairs at Janssen shared his views on the new AGA guidelines on the medical management of moderate-to-severe Crohn’s disease and also highlighted about Janssen’s efforts in improving the QoL of patients with CD The AGA guidelines assessed the overall benefit of each drug and also compared …

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease Read More »

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market

In an interview with PharmaShots, Dennis Williams, SVP Late-stage Development at Adaptimmune shared his views on the Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform and their pathway to bringing the first-ever TCR T-cell therapy for solid tumors to market along with an overview about their industry-leading T-cell therapy pipeline in solid tumors. …

PharmaShots Interview: Adaptimmune’s Dennis Williams Shares Insight About the Company’s Pathway to Bringing the First-Ever TCR T-Cell Therapy for Solid Tumors to Market Read More »

PharmaShots Interview: Kaia Health’s Konstantin Mehl Shares Insight on the Funding to Transform the Treatment for MSK and COPD

In an interview with PharmaShots, Konstantin Mehl, President, CEO, and Founder at Kaia Health shared his views on the grant of $75M Series C funding to expand clinical capabilities & transform the treatment path for musculoskeletal (MSK) and chronic obstructive pulmonary disease (COPD) care in the US and EU. Shots: The funding will extend the …

PharmaShots Interview: Kaia Health’s Konstantin Mehl Shares Insight on the Funding to Transform the Treatment for MSK and COPD Read More »

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Disease Area Leader, Gastroenterology at Janssen Research & Development shared his views on the data regarding the safety & efficacy of Stelara (ustekinumab) for UC patients, including long-term symptomatic & corticosteroid-free remission rates from the UNIFI study. Shots: The P-III UNIFI study evaluates the safety …

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO Read More »

PharmaShots Interview: Prime Therapeutics’ Kelly Pokuta and April Kunze Share Insight on Medical Drug Management Program

In an interview with PharmaShots, Kelly Pokuta, Vice President of Pharmaceutical Trade Relations, and April Kunze, Senior Director, Clinical Formulary Development & Trend Management Strategy at Prime therapeutics share their views on the MedDrive as a first-of-its-kind medical drug management program uniquely aligned with Blue Plan clients. Shots: Prime introduced the first-of-its-kind medical drug management …

PharmaShots Interview: Prime Therapeutics’ Kelly Pokuta and April Kunze Share Insight on Medical Drug Management Program Read More »

PharmaShots Interview: Xencor’s Bassil I. Dahiyat Shares Insight on the US FDA’s Approval of COVID-19 Antibody Treatment Leveraging its Technology

In an interview with PharmaShots, Dr. Bassil I. Dahiyat, President and CEO of Xencor shared his views on the company’s collaborations with BMS and its Xtend XmAb technology. He also shed light on the EUA of Sotrovimab for COVID-19. Shots: The FDA has granted EUA to Vir and GSK’s sotrovimab, which was engineered with Xencor’s …

PharmaShots Interview: Xencor’s Bassil I. Dahiyat Shares Insight on the US FDA’s Approval of COVID-19 Antibody Treatment Leveraging its Technology Read More »

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021

In an interview with PharmaShots, Dr. Lotus Mallbris, M.D., Ph.D., Vice President of Immunology Development at Lilly shared her views on the abstracts demonstrating data on the use of Taltz and Olumiant in rheumatic diseases, including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) for Taltz, and rheumatoid arthritis (RA) for Olumiant.  Shots: Lilly reported that key data from Taltz (ixekizumab) & Olumiant (baricitinib) is highlighted at the …

PharmaShots Interview: Eli Lilly’s Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021 Read More »

PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insight on the US FDA’s Approval of Guardant360 CDx for Amgen’s Lumakras

In an interview with PharmaShots, Justin Odegaard, Vice President of Clinical Development at Guardant Health shares his views on the Guardant360 CDx approval as the first & only liquid biopsy companion diagnostic for Amgen’s Lumakras (sotorasib) KRASG12C inhibitor for use in advanced NSCLC. Shots: Guardant Health received the US FDA’s approval for Guardant360 CDx liquid …

PharmaShots Interview: Guardant Health’s Justin Odegaard Shares Insight on the US FDA’s Approval of Guardant360 CDx for Amgen’s Lumakras Read More »